Should You Buy Vaxart, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Vaxart, Inc. (VXRT) scores a robust 8.1/10 on our 32-signal Quality of Company framework. At the current market price of $0.50 and a $122M market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.
The short answer: 5 of 8 CirclFi valuation models project upside for Vaxart, Inc. (VXRT) at $0.50 — the model consensus leans bullish, with a Quality Score of 8.1/10 and Value-Trap risk of 24/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Vaxart, Inc. (VXRT) in 2026?
What Is the Bull Case vs the Bear Case for Vaxart, Inc. (VXRT)?
| Bull case — $1.65 target (+229.0%) | Bear case — $0.30 target (-39.2%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Vaxart, Inc.'s score of 8.1/10 reflects durable competitive advantages that should sustain earnings power through market cycles. | According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model sees the stock as overvalued with a fair value of $0.30 (-39.2%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the stock shows multi-model upside with a median implied return of +18.5% across 5 bullish models from the current price of $0.50. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +268.3% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model targets a fair value of $1.65 (+229.0%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | Industry headwind: competitive pipeline overlap represents a meaningful risk for Vaxart, Inc. and its Biotechnology peers. |
| Industry tailwind: first-mover advantage in novel targets could provide meaningful support for Vaxart, Inc.'s revenue and margin trajectory in the Biotechnology space. |
How Does VXRT Compare to Its Biotechnology Peers?
Valuation data pages: TGTX · RPRX · KROS · LGND · TBPH · KRYS · NRXS · ANRO · CRBP · EXEL · INCY
Which Other Stocks Score Like VXRT on Quality?
Closest companies to VXRT’s Quality of Company score of 8.1/10, across all industries.
- NTNX — Nutanix, Inc. (QOC 8.1) · analysis
- OLED — Universal Display Corporation (QOC 8.1) · analysis
- WEN — The Wendy's Company (QOC 8.1) · analysis
- FNRN — First Northern Community Bancorp (QOC 8.1) · analysis
- T — AT&T Inc. (QOC 8.1) · analysis
- TROW — T. Rowe Price Group, Inc. (QOC 8.1) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Biotechnology Screens Does VXRT Appear In?
So Is Vaxart, Inc. (VXRT) Worth Buying in 2026?
Vaxart, Inc. leans positive in our analysis — 5/8 models bullish, median fair value of $0.59 vs. $0.50, QOC 8.1/10. The case is constructive but not overwhelming, and the 2 dissenting models shouldn't be dismissed. Position sizing should reflect this moderate conviction level.
These are quantitative model outputs, not investment recommendations. Vaxart, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About VXRT Stock?
Should I buy VXRT stock right now?
Based on CirclFi's multi-model analysis, 5 of 8 models see upside for VXRT at $0.50. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 8.1/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Vaxart, Inc.?
Key risks include: wide model disagreement (441% spread), signaling high uncertainty; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does VXRT compare to its competitors?
Among Biotechnology peers, VXRT holds a Quality Score of 8.1/10. Comparable companies include TGTX (QOC 8.1), RPRX (QOC 8.1), KROS (QOC 8.2). The relative ranking helps investors identify whether VXRT offers better fundamental quality than alternatives in the same sector.
Is VXRT a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. VXRT's Quality Score of 8.1/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy VXRT at?
CirclFi does not provide target buy prices or price alerts. However, our 8 active models produce fair value estimates ranging from $0.30 to $1.65. At $0.50, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for VXRT.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad